Figure 3. ISG20 serum and ISG20 mRNA levels in patients with HBV-related LC.

(A): Comparison of ISG20 levels between patients with and without hepatocellular carcinoma (HCC). (B): Patients with HCC were classified based on categories for Barcelona clinic liver cancer (BCLC) staging, and ISG20 levels were compared between these classified subgroups. P values were calculated by using Mann-Whitney-Wilcoxon test or linear regression adjusted for age and gender where appropriate. (C): Comparison of ISG20 mRNA expression in tumour and adjacent non-tumour tissues. P values were calculated using Paired-samples t-test. (D): ISG20 mRNA expression in stage-A and stage-B tumour tissues and in adjacent non-tumour tissues.